Lansoprazole

Details

• Internal ID: 2d852514-a83a-40f3-8792-02f2a7953a32
• Taxonomy: Organoheterocyclic compounds > Benzimidazoles > Sulfinylbenzimidazoles
• IUPAC Name: 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
• SMILES (Canonical): CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
• SMILES (Isomeric): CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
• InChI: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
• InChI Key: MJIHNNLFOKEZEW-UHFFFAOYSA-N
• Popularity: 6,347 references in papers

Physical and Chemical Properties

• Molecular Formula: C₁₆H₁₄F₃N₃O₂S
• Molecular Weight: 369.40 g/mol
• Exact Mass: 369.07588236 g/mol
• Topological Polar Surface Area (TPSA): 87.10 Ų
• XlogP: 2.80
• Atomic LogP (AlogP): 3.52
• H-Bond Acceptor: 4
• H-Bond Donor: 1
• Rotatable Bonds: 5

Synonyms

• 103577-45-3
• Prevacid
• Limpidex
• Agopton
• Lanzor
• Bamalite
• Monolitum
• Takepron
• Ogastro
• Prevacid SoluTab
• Lansoprazol
• Lanzopral
• Opiren
• Zoton
• Lanproton
• Lansopep
• Lasoprol
• Mesactol
• Aprazol
• Blason
• Ketian
• Lancid
• Lanston
• Lanz
• AG-1749
• lanzoprazole
• Lansoprazolum
• Prosogan
• Suprecid
• Compraz
• Ilsatec
• Lansox
• Zoprol
• Dakar
• Ogast
• Promp
• Prevacid Iv
• PrevOnco
• Lanzol-30
• AG 1749
• A-65006
• Prevacid 24HR
• Prevacid I.V.
• Ogastoro
• Lansoprazol [INN-Spanish]
• Lansoprazolum [INN-Latin]
• Lanzol
• Lanzul
• Lanzo
• Lansoprazole-13C6
• CHEBI:6375
• HSDB 7204
• UNII-0K5C5T2QPG
• 0K5C5T2QPG
• NSC-758638
• 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
• BRN 4333393
• Prezal
• A 65006
• 1261394-42-6
• DTXSID4023200
• Pro Ulco
• 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
• MFCD00866873
• TAK-390MR
• (+/-)-LANSOPRAZOLE
• 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
• 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
• MLS000069705
• DTXCID703200
• Lansoprazole [USAN:USP:INN:BAN]
• PREVPAC COMPONENT LANSOPRAZOLE
• 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-
• 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole
• NSC 758638
• LANSOPRAZOLE COMPONENT OF PREVPAC
• NCGC00015615-02
• SMR000058469
• CAS-103577-45-3
• Lansoprazol (INN-Spanish)
• Lansoprazolum (INN-Latin)
• MLS-0003247.0001
• Prevacid NapraPAC
• 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-
• 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
• 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
• 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
• LANSOPRAZOLE (MART.)
• LANSOPRAZOLE [MART.]
• LANSOPRAZOLE (USP-RS)
• LANSOPRAZOLE [USP-RS]
• TAK 390MR
• Lansoprazoles
• Lansophed
• LANSOPRAZOLE (EP MONOGRAPH)
• LANSOPRAZOLE [EP MONOGRAPH]
• Lansoprazole (USAN:USP:INN:BAN)
• LANSOPRAZOLE (USP MONOGRAPH)
• LANSOPRAZOLE [USP MONOGRAPH]
• 1H-Benzimidazole, 2-[(S)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-
• 2-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole
• Prevacid (TN)
• 2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
• 2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole;2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole
• SR-01000000169
• Lanfast
• Lapraz
• LansoprazoleDR
• Lansoprazole DR
• 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl}-1H-benzimidazole
• ABT-006
• equate lansoprazole
• Lansoprazole,(S)
• Lansoprazole24 HR
• Prevacid 24 Hr
• safeway acid reducer
• Sunmark Lansoprazole
• Topcare Lansoprazole
• Equaline Lansoprazole
• CG-4801
• Dg Health Lansoprazole
• Basic Care Lansoprazole
• Good Sense Lansoprazole
• Spectrum_001580
• Up and Up Lansoprazole
• caring mill lansoprazole
• CPD000058469
• Health Mart Lansoprazole
• Prevacid Delayed Release
• Opera_ID_1676
• Prestwick0_001072
• Prestwick1_001072
• Prestwick2_001072
• Prestwick3_001072
• Spectrum2_000444
• Spectrum3_000295
• Spectrum4_000856
• Spectrum5_001521
• LANSOPRAZOLE [MI]
• Lopac-L-8533
• Heartburn Relief 24 Hour
• LANSOPRAZOLE [INN]
• LANSOPRAZOLE [JAN]
• CHEMBL480
• L 8533
• LANSOPRAZOLE [HSDB]
• LANSOPRAZOLE [USAN]
• lansoprazole delayed release
• cid_3883
• Signature Care Acid Reducer
• LANSOPRAZOLE [VANDF]
• Lopac0_000709
• SCHEMBL22365
• BSPBio_001084
• BSPBio_001830
• KBioGR_001491
• KBioSS_002060
• Lansoprazole impurity standard
• MLS000759405
• MLS001074170
• MLS001424235
• BIDD:GT0006
• DivK1c_000920
• LANSOPRAZOLE [WHO-DD]
• SPECTRUM1503926
• SPBio_000488
• SPBio_002992
• Kirkland Signature Lansoprazole
• Berkley and Jensen Lansoprazole
• BPBio1_001194
• GTPL7208
• BDBM47032
• HMS502N22
• KBio1_000920
• KBio2_002060
• KBio2_004628
• KBio2_007196
• KBio3_001330
• Lansoprazole (JP17/USP/INN)
• A02BC03
• 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
• 2-[(S)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
• Levolansoprazole;(-)-Lansoprazole
• MJIHNNLFOKEZEW-UHFFFAOYSA-O
• NINDS_000920
• HMS1571G06
• HMS1922M04
• HMS2052F05
• HMS2093M07
• HMS2098G06
• HMS2234B10
• HMS3262M19
• HMS3264E12
• HMS3269D15
• HMS3371E21
• HMS3394F05
• HMS3413J05
• HMS3654J17
• HMS3677J05
• HMS3715G06
• LANSOPRAZOLE [ORANGE BOOK]
• Pharmakon1600-01503926
• Pharmakon1600-01504282
• Equate Lansoprazole Delayed Release
• Good Neighbor Pharmacy Lansoprazole
• BCP22331
• BCP34129
• Lansoprazole for peak identification
• Tox21_110184
• Tox21_301023
• Tox21_500709
• BDBM50070208
• CCG-39952
• NSC758638
• NSC758710
• s1354
• AKOS005554811
• Tox21_110184_1
• AC-1233
• CS-1847
• DB00448
• KS-1075
• Lansoprazole, >=98% (TLC), powder
• LP00709
• NC00411
• SB19127
• SDCCGSBI-0050687.P004
• 2-(2-benzimidazolylsulfinylmethyl)-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine
• 2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole
• 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
• IDI1_000920
• NCGC00015615-01
• NCGC00015615-03
• NCGC00015615-04
• NCGC00015615-05
• NCGC00015615-06
• NCGC00015615-07
• NCGC00015615-08
• NCGC00015615-09
• NCGC00015615-10
• NCGC00015615-11
• NCGC00015615-12
• NCGC00015615-14
• NCGC00015615-15
• NCGC00023826-03
• NCGC00023826-04
• NCGC00023826-05
• NCGC00023826-06
• NCGC00023826-07
• NCGC00254925-01
• NCGC00261394-01
• NCGC00381720-13
• BL166173
• HY-13662
• SY052771
• SBI-0050687.P003
• AB00052388
• EU-0100709
• FT-0610894
• FT-0670721
• FT-0670722
• L0233
• SW197226-4
• D00355
• F20528
• Kirkland Signature Lansoprazole Delayed Release
• AB00052388-17
• AB00052388_18
• AB00052388_19
• A800764
• A921066
• Q254296
• J-007154
• SR-01000000169-2
• SR-01000000169-6
• SR-01000000169-9
• BRD-A49172652-001-05-7
• BRD-A49172652-001-13-1
• F2173-0222
• Z1501485356
• Lansoprazole, British Pharmacopoeia (BP) Reference Standard
• Lansoprazole, European Pharmacopoeia (EP) Reference Standard
• Lansoprazole, United States Pharmacopeia (USP) Reference Standard
• (+)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
• 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole
• 2-[[ [3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
• 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]-sulfinyl]1H-benzimidazole
• 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole
• 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
• 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole
• 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]methylsulfinyl]benzimidazole
• 2-[[3-methyl-4-[2,2,2-tris(fluoranyl)ethoxy]pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
• 2-[3-Methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-1H-benzimidazole
• 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-benzimidazole
• 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)pyridin-2-ylmethanesulfinyl]-benzimidazole
• 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl-methanesulfinyl]-1H-benzimidazole
• 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylmethanesulfinyl]-1H-benzimidazole
• Lansoprazole for peak identification, European Pharmacopoeia (EP) Reference Standard
• (RS)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-Benzimidazole
• 2-[[[3-METHYL-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDIN-2-YL]METHYL]SULFINYL]-1H-BENZO[D]IMIDAZOLE

2D Structure

ADMET Properties (via admetSAR 2)

Target	Value	Probability (raw)	Probability (%)
Human Intestinal Absorption	+	1.0000	100.00%
Caco-2	+	0.5000	50.00%
Blood Brain Barrier	+	0.7000	70.00%
Human oral bioavailability	+	0.8714	87.14%
Subcellular localzation	Lysosomes	0.6776	67.76%
OATP2B1 inhibitior	-	1.0000	100.00%
OATP1B1 inhibitior	+	0.9206	92.06%
OATP1B3 inhibitior	+	0.9399	93.99%
MATE1 inhibitior	-	0.9800	98.00%
OCT2 inhibitior	-	0.5250	52.50%
BSEP inhibitior	+	0.6384	63.84%
P-glycoprotein inhibitior	-	0.5737	57.37%
P-glycoprotein substrate	+	0.9343	93.43%
CYP3A4 substrate	+	0.6495	64.95%
CYP2C9 substrate	-	0.7415	74.15%
CYP2D6 substrate	-	0.7813	78.13%
CYP3A4 inhibition	+	0.7959	79.59%
CYP2C9 inhibition	-	0.9071	90.71%
CYP2C19 inhibition	+	0.8993	89.93%
CYP2D6 inhibition	+	0.8932	89.32%
CYP1A2 inhibition	+	0.9106	91.06%
CYP2C8 inhibition	+	0.9151	91.51%
CYP inhibitory promiscuity	+	0.8768	87.68%
UGT catelyzed	-	0.0000	0.00%
Carcinogenicity (binary)	-	0.7126	71.26%
Carcinogenicity (trinary)	Non-required	0.5031	50.31%
Eye corrosion	-	0.9835	98.35%
Eye irritation	-	0.8562	85.62%
Skin irritation	-	0.7669	76.69%
Skin corrosion	-	0.9182	91.82%
Ames mutagenesis	+	0.5300	53.00%
Human Ether-a-go-go-Related Gene inhibition	+	0.6525	65.25%
Micronuclear	+	0.8800	88.00%
Hepatotoxicity	+	0.7500	75.00%
skin sensitisation	-	0.8268	82.68%
Respiratory toxicity	+	0.9444	94.44%
Reproductive toxicity	+	0.8333	83.33%
Mitochondrial toxicity	+	0.9500	95.00%
Nephrotoxicity	-	0.5584	55.84%
Acute Oral Toxicity (c)	III	0.7770	77.70%
Estrogen receptor binding	+	0.7074	70.74%
Androgen receptor binding	+	0.8236	82.36%
Thyroid receptor binding	+	0.6904	69.04%
Glucocorticoid receptor binding	-	0.5000	50.00%
Aromatase binding	-	0.5071	50.71%
PPAR gamma	+	0.7555	75.55%
Honey bee toxicity	-	0.8845	88.45%
Biodegradation	-	0.7000	70.00%
Crustacea aquatic toxicity	-	0.5100	51.00%
Fish aquatic toxicity	+	0.8984	89.84%

Targets

Proven Targets:

No proven targets yet!

Predicted Targets (via Super-PRED):

CHEMBL ID	UniProt ID	Name	Probability	Model accuracy
CHEMBL255	P29275	Adenosine A2b receptor	94.73%	98.59%
CHEMBL3524	P56524	Histone deacetylase 4	94.41%	92.97%
CHEMBL2581	P07339	Cathepsin D	92.94%	98.95%
CHEMBL2635	P51452	Dual specificity protein phosphatase 3	92.66%	94.00%
CHEMBL1868	P17948	Vascular endothelial growth factor receptor 1	92.66%	96.47%
CHEMBL3251	P19838	Nuclear factor NF-kappa-B p105 subunit	91.75%	96.09%
CHEMBL240	Q12809	HERG	91.12%	89.76%
CHEMBL3401	O75469	Pregnane X receptor	90.93%	94.73%
CHEMBL5409	Q8TDU6	G-protein coupled bile acid receptor 1	90.59%	93.65%
CHEMBL2535	P11166	Glucose transporter	89.30%	98.75%
CHEMBL2378	P30307	Dual specificity phosphatase Cdc25C	88.99%	96.67%
CHEMBL1293249	Q13887	Kruppel-like factor 5	87.40%	86.33%
CHEMBL1075094	Q16236	Nuclear factor erythroid 2-related factor 2	86.78%	96.00%
CHEMBL3310	Q96DB2	Histone deacetylase 11	86.01%	88.56%
CHEMBL4145	Q9UKV0	Histone deacetylase 9	85.03%	85.49%
CHEMBL3038477	P67870	Casein kinase II alpha/beta	84.94%	99.23%
CHEMBL2095226	P05556	Integrin alpha-5/beta-1	83.15%	96.39%
CHEMBL3108638	O15164	Transcription intermediary factor 1-alpha	82.90%	95.56%
CHEMBL3060	Q9Y345	Glycine transporter 2	82.66%	99.17%
CHEMBL2335	P42785	Lysosomal Pro-X carboxypeptidase	82.21%	100.00%
CHEMBL1806	P11388	DNA topoisomerase II alpha	81.79%	89.00%

Plants that contains it

There are no matching plants.

Cross-Links

• PubChem: 3883
• LOTUS: LTS0245838
• wikiData: Q254296